90 Chapter 4 Author Coinfections tested Patients tested (all positive for SARSCoV-2) Coinfections (%) Influenza coinfection (%) RSV coinfection (%) Adeno coinfection (%) Kim (2021), Australia RV, influenza 92 7 (8) 2 (2) 0 (0) 0 (0) Nowak (2020), USA AV, HCoV (NL63, HKU1, 229E, OC43), MPV, RV, Influenza, PIV, RSV 1204 37 (3.1) 1 (0.1) 4 (0.3) 2 (0.2) Singh (2021), USA AV, HCoV (NL63, HKU1, 229E, OC43), MPV, RV, Influenza, BV, PIV, RSV, EBV, HHV6, VZV 4259 146 (3.4) 1 (<0.1) 5 (0.1) 13 (0.3) Takahashi (2020), USA Influenza 902 3 (0.3) 3 (0.3) NA NA Supplementary table 1. AV = Adenovirus, BV= Bocavirus, PIV=parainfluenza virus, MPV= human metapneumovirus, HHV= human herpes virus 6, EBV = epstein barr virus, RV = rhinovirus, VZV= varicella zoster virus. *This was a report prepared by the ISARIC4C investigators as part of the COVID-19 Clinical Information Network (CO-CIN) for the UK Scientific Advisory Group for Emergencies (SAGE); it includes some overlapping patients and also includes children. The original SAGE report is available here: https://www.gov. uk/government/publications/co-cin-influenza-infection-in-patients-hospitalised-with-covid-19-rapid-reportfrom-co-cin-data-23-september-2020
RkJQdWJsaXNoZXIy MTk4NDMw